Otsuka Pharmaceutical & Click Therapeutics Launch Clinical Trial For Digital Therapeutic As Adjunct Treatment For Depression

Otsuka Pharmaceutical and Click Therapeutics launched a new, fully remote clinical trial of a digital therapeutic intervention focused on depression. The trial, called the Mirai study, is being conducted on Verily's Project Baseline platform. It is testing the effectiveness of the digital therapeutic as an adjunct treatment in reducing symptoms of depression among adults taking an antidepressant for major depressive disorder (MDD).

The randomized, controlled trial will enroll up to 540 participants across the United States. Trial participation will be 10 weeks, and efficacy will be evaluated as a change from baseline in the Montgomery–Åsberg Depression Rating Scale . . .